Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.

نویسندگان

  • Timothy R Rebbeck
  • Nandita Mitra
  • Fei Wan
  • Olga M Sinilnikova
  • Sue Healey
  • Lesley McGuffog
  • Sylvie Mazoyer
  • Georgia Chenevix-Trench
  • Douglas F Easton
  • Antonis C Antoniou
  • Katherine L Nathanson
  • Yael Laitman
  • Anya Kushnir
  • Shani Paluch-Shimon
  • Raanan Berger
  • Jamal Zidan
  • Eitan Friedman
  • Hans Ehrencrona
  • Marie Stenmark-Askmalm
  • Zakaria Einbeigi
  • Niklas Loman
  • Katja Harbst
  • Johanna Rantala
  • Beatrice Melin
  • Dezheng Huo
  • Olufunmilayo I Olopade
  • Joyce Seldon
  • Patricia A Ganz
  • Robert L Nussbaum
  • Salina B Chan
  • Kunle Odunsi
  • Simon A Gayther
  • Susan M Domchek
  • Banu K Arun
  • Karen H Lu
  • Gillian Mitchell
  • Beth Y Karlan
  • Christine Walsh
  • Jenny Lester
  • Andrew K Godwin
  • Harsh Pathak
  • Eric Ross
  • Mary B Daly
  • Alice S Whittemore
  • Esther M John
  • Alexander Miron
  • Mary Beth Terry
  • Wendy K Chung
  • David E Goldgar
  • Saundra S Buys
  • Ramunas Janavicius
  • Laima Tihomirova
  • Nadine Tung
  • Cecilia M Dorfling
  • Elizabeth J van Rensburg
  • Linda Steele
  • Susan L Neuhausen
  • Yuan Chun Ding
  • Bent Ejlertsen
  • Anne-Marie Gerdes
  • Thomas v O Hansen
  • Teresa Ramón y Cajal
  • Ana Osorio
  • Javier Benitez
  • Javier Godino
  • Maria-Isabel Tejada
  • Mercedes Duran
  • Jeffrey N Weitzel
  • Kristie A Bobolis
  • Sharon R Sand
  • Annette Fontaine
  • Antonella Savarese
  • Barbara Pasini
  • Bernard Peissel
  • Bernardo Bonanni
  • Daniela Zaffaroni
  • Francesca Vignolo-Lutati
  • Giulietta Scuvera
  • Giuseppe Giannini
  • Loris Bernard
  • Maurizio Genuardi
  • Paolo Radice
  • Riccardo Dolcetti
  • Siranoush Manoukian
  • Valeria Pensotti
  • Viviana Gismondi
  • Drakoulis Yannoukakos
  • Florentia Fostira
  • Judy Garber
  • Diana Torres
  • Muhammad Usman Rashid
  • Ute Hamann
  • Susan Peock
  • Debra Frost
  • Radka Platte
  • D Gareth Evans
  • Rosalind Eeles
  • Rosemarie Davidson
  • Diana Eccles
  • Trevor Cole
  • Jackie Cook
  • Carole Brewer
  • Shirley Hodgson
  • Patrick J Morrison
  • Lisa Walker
  • Mary E Porteous
  • M John Kennedy
  • Louise Izatt
  • Julian Adlard
  • Alan Donaldson
  • Steve Ellis
  • Priyanka Sharma
  • Rita Katharina Schmutzler
  • Barbara Wappenschmidt
  • Alexandra Becker
  • Kerstin Rhiem
  • Eric Hahnen
  • Christoph Engel
  • Alfons Meindl
  • Stefanie Engert
  • Nina Ditsch
  • Norbert Arnold
  • Hans Jörg Plendl
  • Christoph Mundhenke
  • Dieter Niederacher
  • Markus Fleisch
  • Christian Sutter
  • C R Bartram
  • Nicola Dikow
  • Shan Wang-Gohrke
  • Dorothea Gadzicki
  • Doris Steinemann
  • Karin Kast
  • Marit Beer
  • Raymonda Varon-Mateeva
  • Andrea Gehrig
  • Bernhard H Weber
  • Dominique Stoppa-Lyonnet
  • Olga M Sinilnikova
  • Sylvie Mazoyer
  • Claude Houdayer
  • Muriel Belotti
  • Marion Gauthier-Villars
  • Francesca Damiola
  • Nadia Boutry-Kryza
  • Christine Lasset
  • Hagay Sobol
  • Jean-Philippe Peyrat
  • Danièle Muller
  • Jean-Pierre Fricker
  • Marie-Agnès Collonge-Rame
  • Isabelle Mortemousque
  • Catherine Nogues
  • Etienne Rouleau
  • Claudine Isaacs
  • Anne De Paepe
  • Bruce Poppe
  • Kathleen Claes
  • Kim De Leeneer
  • Marion Piedmonte
  • Gustavo Rodriguez
  • Katie Wakely
  • John Boggess
  • Stephanie V Blank
  • Jack Basil
  • Masoud Azodi
  • Kelly-Anne Phillips
  • Trinidad Caldes
  • Miguel de la Hoya
  • Atocha Romero
  • Heli Nevanlinna
  • Kristiina Aittomäki
  • Annemarie H van der Hout
  • Frans B L Hogervorst
  • Senno Verhoef
  • J Margriet Collée
  • Caroline Seynaeve
  • Jan C Oosterwijk
  • Johannes J P Gille
  • Juul T Wijnen
  • Encarna B Gómez Garcia
  • Carolien M Kets
  • Margreet G E M Ausems
  • Cora M Aalfs
  • Peter Devilee
  • Arjen R Mensenkamp
  • Ava Kwong
  • Edith Olah
  • Janos Papp
  • Orland Diez
  • Conxi Lazaro
  • Esther Darder
  • Ignacio Blanco
  • Mónica Salinas
  • Anna Jakubowska
  • Jan Lubinski
  • Jacek Gronwald
  • Katarzyna Jaworska-Bieniek
  • Katarzyna Durda
  • Grzegorz Sukiennicki
  • Tomasz Huzarski
  • Tomasz Byrski
  • Cezary Cybulski
  • Aleksandra Toloczko-Grabarek
  • Elżbieta Złowocka-Perłowska
  • Janusz Menkiszak
  • Adalgeir Arason
  • Rosa B Barkardottir
  • Jacques Simard
  • Rachel Laframboise
  • Marco Montagna
  • Simona Agata
  • Elisa Alducci
  • Ana Peixoto
  • Manuel R Teixeira
  • Amanda B Spurdle
  • Min Hyuk Lee
  • Sue K Park
  • Sung-Won Kim
  • Tara M Friebel
  • Fergus J Couch
  • Noralane M Lindor
  • Vernon S Pankratz
  • Lucia Guidugli
  • Xianshu Wang
  • Marc Tischkowitz
  • Lenka Foretova
  • Joseph Vijai
  • Kenneth Offit
  • Mark Robson
  • Rohini Rau-Murthy
  • Noah Kauff
  • Anneliese Fink-Retter
  • Christian F Singer
  • Christine Rappaport
  • Daphne Gschwantler-Kaulich
  • Georg Pfeiler
  • Muy-Kheng Tea
  • Andreas Berger
  • Mark H Greene
  • Phuong L Mai
  • Evgeny N Imyanitov
  • Amanda Ewart Toland
  • Leigha Senter
  • Anders Bojesen
  • Inge Sokilde Pedersen
  • Anne-Bine Skytte
  • Lone Sunde
  • Mads Thomassen
  • Sanne Traasdahl Moeller
  • Torben A Kruse
  • Uffe Birk Jensen
  • Maria Adelaide Caligo
  • Paolo Aretini
  • Soo-Hwang Teo
  • Christina G Selkirk
  • Peter J Hulick
  • Irene Andrulis
چکیده

IMPORTANCE Limited information about the relationship between specific mutations in BRCA1 or BRCA2 (BRCA1/2) and cancer risk exists. OBJECTIVE To identify mutation-specific cancer risks for carriers of BRCA1/2. DESIGN, SETTING, AND PARTICIPANTS Observational study of women who were ascertained between 1937 and 2011 (median, 1999) and found to carry disease-associated BRCA1 or BRCA2 mutations. The international sample comprised 19,581 carriers of BRCA1 mutations and 11,900 carriers of BRCA2 mutations from 55 centers in 33 countries on 6 continents. We estimated hazard ratios for breast and ovarian cancer based on mutation type, function, and nucleotide position. We also estimated RHR, the ratio of breast vs ovarian cancer hazard ratios. A value of RHR greater than 1 indicated elevated breast cancer risk; a value of RHR less than 1 indicated elevated ovarian cancer risk. EXPOSURES Mutations of BRCA1 or BRCA2. MAIN OUTCOMES AND MEASURES Breast and ovarian cancer risks. RESULTS Among BRCA1 mutation carriers, 9052 women (46%) were diagnosed with breast cancer, 2317 (12%) with ovarian cancer, 1041 (5%) with breast and ovarian cancer, and 7171 (37%) without cancer. Among BRCA2 mutation carriers, 6180 women (52%) were diagnosed with breast cancer, 682 (6%) with ovarian cancer, 272 (2%) with breast and ovarian cancer, and 4766 (40%) without cancer. In BRCA1, we identified 3 breast cancer cluster regions (BCCRs) located at c.179 to c.505 (BCCR1; RHR = 1.46; 95% CI, 1.22-1.74; P = 2 × 10(-6)), c.4328 to c.4945 (BCCR2; RHR = 1.34; 95% CI, 1.01-1.78; P = .04), and c. 5261 to c.5563 (BCCR2', RHR = 1.38; 95% CI, 1.22-1.55; P = 6 × 10(-9)). We also identified an ovarian cancer cluster region (OCCR) from c.1380 to c.4062 (approximately exon 11) with RHR = 0.62 (95% CI, 0.56-0.70; P = 9 × 10(-17)). In BRCA2, we observed multiple BCCRs spanning c.1 to c.596 (BCCR1; RHR = 1.71; 95% CI, 1.06-2.78; P = .03), c.772 to c.1806 (BCCR1'; RHR = 1.63; 95% CI, 1.10-2.40; P = .01), and c.7394 to c.8904 (BCCR2; RHR = 2.31; 95% CI, 1.69-3.16; P = .00002). We also identified 3 OCCRs: the first (OCCR1) spanned c.3249 to c.5681 that was adjacent to c.5946delT (6174delT; RHR = 0.51; 95% CI, 0.44-0.60; P = 6 × 10(-17)). The second OCCR spanned c.6645 to c.7471 (OCCR2; RHR = 0.57; 95% CI, 0.41-0.80; P = .001). Mutations conferring nonsense-mediated decay were associated with differential breast or ovarian cancer risks and an earlier age of breast cancer diagnosis for both BRCA1 and BRCA2 mutation carriers. CONCLUSIONS AND RELEVANCE Breast and ovarian cancer risks varied by type and location of BRCA1/2 mutations. With appropriate validation, these data may have implications for risk assessment and cancer prevention decision making for carriers of BRCA1 and BRCA2 mutations.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

جهش های ژنتیکی جدید در ژن های اصلی سرطان پستان (BRCA1/BRCA2) در زنان ایرانی مبتلا به سرطان پستان زودرس

Background: Breast cancer is the most common female malignancy and the main cause of death in  mid-aged women. Genetic germ line mutations in BRCAI/BRCA2 in Iranian women with breast or  ovarian cancer have not been yet reported. Materials and methods: Clinical data, family history and blood samples were obtained from 83  females aged less than 45 years with primary breast cancer in order to su...

متن کامل

وقوع و سهم تغییرات توالی ژن‌های BRCA1/2 در سلول زایشی مبتلایان سرطان پستان

Normal 0 false false false EN-US X-NONE AR-SA MicrosoftInternetExplorer4 /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal" mso-tstyle-rowband-size:0 mso-tstyle-colband-size:0 mso-style-noshow:yes mso-style-priority:99 mso-style-qformat:yes ms...

متن کامل

بررسی موتاسیون های شایع ژن BRCA1 و BRCA2 در دختران مادران مبتلا به سرطان سینه و مقایسه آن با گروه کنترل

Background and purpose: Breast Cancer is one of the health problems in every population. The aim of this study was to determine the frequency of BRCA1 and BRCA2 common mutations in women whose mothers were diagnosed with breast cancer. Materials and methods: A case–control study was performed in 109 females (less than 40 years of age) who had mothers with breast cancer. For scanning of...

متن کامل

Women with hereditary breast cancer predispositions should avoid using their smartphones, tablets and laptops at night

Breast cancer is the most common malignancy among women, both in the developed and developing countries. Women with mutations in the BRCA1 and BRCA2 genes have an increased risk of breast and ovarian cancers. Recent studies show that short-wavelength visible light disturb the secretion of melatonin and causes circadian rhythm disruption. We have previously studied the health effects of exposure...

متن کامل

Genetic diagnosis of cancer: diagnosis of mutations in BRCA1 and BRCA2 in breast cancer

During the last two decays the tremendous success in molecular biology and genetics which has surprised the entire world. So that today the sequencing of whole genome has been possible for each human individual to estimate its being affected with cardiovascular and cancer diseases. However, these achievements have some important limitations and deep ethical issues which might be ignored. Geneti...

متن کامل

The importance of BRCA1 and BRCA2 genes mutations in breast cancer development

Many factors including genetic, environmental, and acquired are involved in breast cancer development across various societies. Among all of these factors in families with a history of breast cancer throughout several generations, genetics, like predisposing genes to develop this disease, should be considered more. Early detection of mutation carriers in these genes, in turn, can play an import...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • JAMA

دوره 313 13  شماره 

صفحات  -

تاریخ انتشار 2015